4XEW image
Deposition Date 2014-12-25
Release Date 2015-07-08
Last Version Date 2023-09-27
Entry Detail
PDB ID:
4XEW
Title:
Crystal structure of 7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, complexed with a HTS lead compound
Biological Source:
Method Details:
Experimental Method:
Resolution:
2.47 Å
R-Value Free:
0.21
R-Value Work:
0.16
R-Value Observed:
0.16
Space Group:
P 21 21 21
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Adenosylmethionine-8-amino-7-oxononanoate aminotransferase
Gene (Uniprot):bioA
Chain IDs:A, B
Chain Length:457
Number of Molecules:2
Biological Source:Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)
Primary Citation
Fragment-Based Exploration of Binding Site Flexibility in Mycobacterium tuberculosis BioA.
J.Med.Chem. 58 5208 5217 (2015)
PMID: 26068403 DOI: 10.1021/acs.jmedchem.5b00092

Abstact

The PLP-dependent transaminase (BioA) of Mycobacterium tuberculosis and other pathogens that catalyzes the second step of biotin biosynthesis is a now well-validated target for antibacterial development. Fragment screening by differential scanning fluorimetry has been performed to discover new chemical scaffolds and promote optimization of existing inhibitors. Calorimetry confirms binding of six molecules with high ligand efficiency. Thermodynamic data identifies which molecules bind with the enthalpy driven stabilization preferred in compounds that represent attractive starting points for future optimization. Crystallographic characterization of complexes with these molecules reveals the dynamic nature of the BioA active site. Different side chain conformational states are stabilized in response to binding by different molecules. A detailed analysis of conformational diversity in available BioA structures is presented, resulting in the identification of two states that might be targeted with molecular scaffolds incorporating well-defined conformational attributes. This new structural data can be used as part of a scaffold hopping strategy to further optimize existing inhibitors or create new small molecules with improved therapeutic potential.

Legend

Protein

Chemical

Disease

Primary Citation of related structures